- Conditions
- Glioblastoma
- Interventions
- 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Duarte, California • Santa Monica, California • New Orleans, Louisiana + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor
- Interventions
- aldoxorubicin
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin
- Drug · Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Malignant Solid Tumour
- Interventions
- INNO-206
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Advanced Solid Tumors
- Interventions
- aldoxorubicin
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
- Interventions
- 170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Sarcoma
- Interventions
- aldoxorubicin
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Small Cell Lung Cancer
- Interventions
- Aldoxorubicin, Topotecan
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Pasadena, California • Fleming Island, Florida + 8 more
- Conditions
- Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Interventions
- INNO-206, Doxorubicin
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Stanford, California • Iowa City, Iowa + 2 more
- Conditions
- Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
- Interventions
- Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- INNO-206
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Billings, Montana • Albany, New York + 4 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- INNO-206
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
- Conditions
- Metastatic Solid Tumors
- Interventions
- aldoxorubicin, gemcitabine
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Santa Monica, California